KR20010052791A - 치료용 비아릴 유도체 - Google Patents
치료용 비아릴 유도체 Download PDFInfo
- Publication number
- KR20010052791A KR20010052791A KR1020007014098A KR20007014098A KR20010052791A KR 20010052791 A KR20010052791 A KR 20010052791A KR 1020007014098 A KR1020007014098 A KR 1020007014098A KR 20007014098 A KR20007014098 A KR 20007014098A KR 20010052791 A KR20010052791 A KR 20010052791A
- Authority
- KR
- South Korea
- Prior art keywords
- amino
- ethyl
- chlorophenyl
- biphenyl
- hydroxyethyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
- C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims (18)
- 하기 화학식 I의 화합물 또는 그의 약학적으로 허용가능한 유도체.<화학식 I>상기 식에서, R1은 페닐, 나프틸, 피리딜, 티아졸릴, 페녹시메틸, 또는 피리미딜기(이들은 할로겐, 히드록시, C1-6알콕시, C1-6알킬, 니트로, 시아노, 히드록시메틸, 트리플루오로메틸, -NR6R6및 -NHSO2R6(여기서 각 R6은 독립적으로 수소 또는 C1-4알킬임)로 이루어진 군으로부터 선택된 1 이상의 치환기로 임의 치환됨)이고;R2는 수소 또는 C1-6알킬이고;X는 산소, 황, -NH 또는 -NC1-4알킬이고;R3는 시아노, 테트라졸-5-일 또는 -CO2R7(여기서 R7은 수소 또는 C1-6알킬임)이고;R4및 R5는 독립적으로 수소, C1-6알킬, -CO2H, -CO2C1-6알킬, 시아노, 테트라졸-5-일, 할로겐, 트리플루오로메틸 또는 C1-6알콕시이거나, R4및 R5가 인접 탄소원자에 결합되는 경우에는, R4및 R5는 결합된 탄소원자와 함께, 경우에 따라 1 또는 2개의 질소, 산소 또는 황 원자를 함유하는, 융합 5 또는 6원 고리를 형성하고;Y는 N 또는 CH이다.
- 제1항에 있어서, R1이, 할로겐, 히드록시, C1-6알콕시, C1-6알킬, 니트로, 시아노, 히드록시메틸 및 트리플루오로메틸로부터 선택된 1, 2 또는 3개의 치환기로 임의 치환된, 페녹시메틸 또는 페닐인 화합물.
- 제1 또는 2항에 있어서, R1이, 염소, 불소, 브롬, 메틸 또는 트리플루오로메틸로 치환된, 페녹시메틸 또는 페닐인 화합물.
- 제1 내지 3항 중 어느 한 항에 있어서, R2가 수소 또는 메틸인 화합물.
- 제1 내지 4항 중 어느 한 항에 있어서, R2가 수소인 화합물.
- 제1 내지 5항 중 어느 한 항에 있어서, X가 NH인 화합물.
- 제1 내지 6항 중 어느 한 항에 있어서, R3가 CO2H인 화합물.
- 제1 내지 7항 중 어느 한 항에 있어서, 1 이상의 R4및 R5가 수소인 화합물.
- 제1 내지 8항 중 어느 한 항에 있어서, R4및 R5가 둘 다 수소인 화합물.
- 제1 내지 9항 중 어느 한 항에 있어서, Y가 CH인 화합물.
- 제1항에 있어서, R1이 염소, 불소, 브롬, 메틸, 또는 트리플루오로메틸로 치환된, 페녹시메틸 또는 페닐이고; R2가 수소 또는 메틸이고; X가 NH 또는 NCH3이고; R3가 CO2H이고; Y가 CH인 화합물.
- (R)-3'-[[2-[[2-(3-클로로페닐)-2-히드록시에틸]아미노]에틸]아미노]-[1.1'-비페닐]-3-카르복실산 메틸 에스테르;(R)-3'-[[2-[[2-(3-클로로페닐)-2-히드록시에틸]아미노]에틸]아미노]-[1.1'-비페닐]-2,4-디카르복실산 디메틸 에스테르;(R)-3'-[[2-[[2-(3-클로로페닐)-2-히드록시에틸]아미노]에틸]아미노]-[1.1'-비페닐]-2-메틸-5-카르복실산 메틸 에스테르;(R)-3'-[[2-[[2-(3-클로로페닐)-2-히드록시에틸]아미노]에틸]아미노]-[1.1'-비페닐]-3,4-디카르복실산 디메틸 에스테르;(R)-3'-[[2-[[2-(3-클로로페닐)-2-히드록시에틸]아미노]에틸]아미노]-[1.1'-비페닐]-3-클로로-4-카르복실산 메틸 에스테르;(R)-3'-[[2-[[2-(3,5-디클로로페닐)-2-히드록시에틸]아미노]에틸]아미노]-[1.1'-비페닐]-3-카르복실산 메틸 에스테르;(R)-3'-[[2-[[2-(3,5-디클로로페닐)-2-히드록시에틸]아미노]에틸]아미노]-[1.1'-비페닐]-3-카르복실산;(R)-3'-[[2-[[2-(3-클로로페닐)-2-히드록시에틸]아미노]에틸]아미노]-[1.1'-비페닐]-3-카르복실산;(R)-3'-[[2-[[2-(3-클로로페닐)-2-히드록시에틸]아미노]에틸]아미노]-[1.1'-비페닐]-2,4-디카르복실산 2-메틸 에스테르;(R)-3'-[[2-[[2-(3-클로로페닐)-2-히드록시에틸]아미노]에틸]아미노]-[1.1'-비페닐]-2,4-디카르복실산;(R)-3'-[[2-[[2-(3-클로로페닐)-2-히드록시에틸]아미노]에틸]아미노]-[1.1'-비페닐]-2-메틸-5-카르복실산;(R)-3'-[[2-[[2-(3-클로로페닐)-2-히드록시에틸]아미노]에틸]아미노]-[1.1'-비페닐]-3-클로로-4-카르복실산;(R)-3'-[[2-[[2-(3-클로로페닐)-2-히드록시에틸]아미노]에틸]아미노]-[1.1'-비페닐]-3,4-디카르복실산;(R)-3'-[[2-[(2-히드록시-3-페녹시프로필)아미노]에틸]아미노]-[1.1'-비페닐]-3-카르복실산;(R)-3'-[2-[[2-(3-클로로페닐)-2-히드록시에틸]아미노]에톡시]-[1.1'-비페닐]-3-카르복실산;3'-[[2R-[[2-(3-클로로페닐)-2R-히드록시에틸]아미노]프로필]아미노]-[1.1'-비페닐]-4-카르복실산;3'-[[2R-[[2-(3-클로로페닐)-2R-히드록시에틸]아미노]프로필]아미노]-[1.1'-비페닐]-2-카르복실산;3'-[[2R-[[2-(3-클로로페닐)-2R-히드록시에틸]아미노]프로필]아미노]-[1.1'-비페닐]-2,4-디카르복실산;5-[3-[[2R-[[2-(3-클로로페닐)-2R-히드록시에틸]아미노]프로필]아미노]페닐]3-피리딘카르복실산;2-[3-[[2R-[[2-(3-클로로페닐)-2R-히드록시에틸]아미노]프로필]아미노]페닐]-3-피리딘카르복실산;(R)-5-[3-[[2-[[2-(3-클로로페닐)-2-히드록시에틸]아미노]에틸]아미노]페닐]-2,3-디히드로-7-벤조푸란카르복실산;(R)-5-[3-[[2-[[2-(3-클로로페닐)-2-히드록시에틸]아미노]에틸]아미노]페닐]-3-피리딘카르복실산;(R)-2-[3-[[2-[[2-(3-클로로페닐)-2-히드록시에틸]아미노]에틸]아미노]페닐]-4-피리딘카르복실산;(R)-3'-[[2-[[2-(3-클로로페닐)-2-히드록시에틸]아미노]에틸]아미노]-[1.1'-비페닐]-3-(1H-5-테트라졸);(R)-3'-[[2-[[2-(3-클로로페닐)-2-히드록시에틸]아미노]에틸]아미노]-[1.1'-비페닐]-3-카르보니트릴; 및(R)-2-[3-[[2-[[2-(3-클로로페닐)-2-히드록시에틸]아미노]에틸]아미노]페닐]-2-피리딘카르복실산으로 이루어진 군으로부터 선택된 화합물 또는 그의 약학적으로 허용가능한 유도체.
- (R)-5-[3-[[2-[[2-(3-클로로페닐)-2-히드록시에틸]아미노]에틸]아미노]페닐]-3-피리딘카르복실산;3'-[[2R-[[2-(3-클로로페닐)-2R-히드록시에틸]아미노]프로필]아미노]-[1.1'-비페닐]-2,4-디카르복실산;(R)-3'-[[2-[(2-히드록시-3-페녹시프로필)아미노]에틸]아미노]-[1.1'-비페닐]-3-카르복실산;(R)-3'-[[2-[[2-(3-클로로페닐)-2-히드록시에틸]아미노]에틸]아미노]-[1.1'-비페닐]-2-메틸-5-카르복실산; 및(R)-3'-[[2-[[2-(3-클로로페닐)-2-히드록시에틸]아미노]에틸]아미노]-[1.1'-비페닐]-3-카르복실산으로 이루어진 군으로부터 선택된 화합물 또는 그의 약학적으로 허용가능한 유도체.
- 제1 내지 13항중 어느 한 항에 있어서, 치료에 사용하기 위한 화합물.
- 비전형적 베타-아드레날린수용체 아고니스트에 의해 회복될 수 있는 상태에 대한, 인간을 포함한 포유류의 치료용 약물의 제조에 있어서, 제1 내지 13항 중 어느 한 항에 따른 화합물의 용도.
- 제1 내지 13항 중 어느 한 항에 따른 화합물 또는 그의 약학적으로 허용가능한 염의 유효량을 투여하는 것을 포함하는, 비전형적 베타-아드레날린수용체 아고니스트에 의해 회복될 수 있는 상태에 대한, 인간을 포함한 포유류의 치료 방법.
- 1종 이상의 약학적으로 허용가능한 담체와 함께, 제1 내지 13항 중 어느 한 항에 따른 화합물 또는 그의 약학적으로 허용가능한 염을 포함하는 약학적 조성물.
- (A) 하기 화학식 II의 화합물을 탈보호시키거나<화학식 II>;(B) 화학식 I의 또다른 화합물로 상호전환시키거나;(C) 하기 화학식 III의 화합물을 하기 화학식 IV의 화합물과 반응시킨 후, 이어서 중간 생성물을 정제하지 않고 상기 단계 (A)를 행하거나; 또는<화학식 III><화학식 IV>(D) 하기 화학식 VIII의 화합물을 하기 화학식 IX의 화합물과 반응시키는 것을 포함하는, 화학식 I의 화합물의 제조 방법.<화학식 VIII><화학식 IX>
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9812709.5A GB9812709D0 (en) | 1998-06-13 | 1998-06-13 | Chemical compounds |
GB9812709.5 | 1998-06-13 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20010052791A true KR20010052791A (ko) | 2001-06-25 |
KR100415877B1 KR100415877B1 (ko) | 2004-01-24 |
Family
ID=10833658
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR10-2000-7014098A KR100415877B1 (ko) | 1998-06-13 | 1999-06-09 | 치료용 비아릴 유도체 |
Country Status (38)
Country | Link |
---|---|
US (1) | US6251925B1 (ko) |
EP (1) | EP1087943B1 (ko) |
JP (1) | JP3471754B2 (ko) |
KR (1) | KR100415877B1 (ko) |
CN (1) | CN1214008C (ko) |
AP (1) | AP1687A (ko) |
AR (1) | AR029301A1 (ko) |
AT (1) | ATE302189T1 (ko) |
AU (1) | AU753004B2 (ko) |
BR (1) | BR9911182B1 (ko) |
CA (1) | CA2334713C (ko) |
CO (1) | CO5060482A1 (ko) |
CZ (1) | CZ299172B6 (ko) |
DE (1) | DE69926752T2 (ko) |
DK (1) | DK1087943T3 (ko) |
EA (1) | EA003641B1 (ko) |
EE (1) | EE04435B1 (ko) |
EG (1) | EG23856A (ko) |
ES (1) | ES2245107T3 (ko) |
GB (1) | GB9812709D0 (ko) |
HK (1) | HK1034253A1 (ko) |
HR (1) | HRP20000854B1 (ko) |
HU (1) | HUP0102668A3 (ko) |
ID (1) | ID27841A (ko) |
IL (2) | IL140219A0 (ko) |
IS (1) | IS2277B (ko) |
MY (1) | MY119542A (ko) |
NO (1) | NO318782B1 (ko) |
NZ (1) | NZ508805A (ko) |
PE (1) | PE20000726A1 (ko) |
PL (1) | PL196943B1 (ko) |
RS (1) | RS49921B (ko) |
SI (1) | SI1087943T1 (ko) |
SK (1) | SK286256B6 (ko) |
TR (1) | TR200100299T2 (ko) |
TW (1) | TWI244471B (ko) |
WO (1) | WO1999065877A1 (ko) |
ZA (1) | ZA200007417B (ko) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9929118D0 (en) * | 1999-12-10 | 2000-02-02 | Glaxo Group Ltd | Chemical compounds |
GB9929297D0 (en) * | 1999-12-11 | 2000-02-02 | Glaxo Group Ltd | Process |
DE10005150A1 (de) * | 2000-02-07 | 2001-08-09 | Merck Patent Gmbh | Verfahren zur Herstellung von 5-Arylnicotinaldehyden |
AP2001002307A0 (en) | 2000-10-20 | 2001-12-31 | Pfizer Prod Inc | B3 adrenergic receptor agonists and uses thereof. |
AR035605A1 (es) | 2000-12-11 | 2004-06-16 | Bayer Corp | Derivados de aminometil cromano di-sustituidos, un metodo para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la manufactura de medicamentos utiles como agonistas beta-3-adreno-receptores |
US7709677B2 (en) | 2001-01-31 | 2010-05-04 | Glaxosmithkline Llc | Process of preparing arylethanoldiamines |
GB0102407D0 (en) * | 2001-01-31 | 2001-03-14 | Glaxo Group Ltd | Process |
US7034053B2 (en) | 2001-01-31 | 2006-04-25 | Smithkline Beecham Corporation | Phenethanolamine derivatives, compositions, and their use as agonists at atypical beta-adrenoreceptors |
GB0102408D0 (en) * | 2001-01-31 | 2001-03-14 | Glaxo Group Ltd | Chemical compounds |
EP1236723A1 (en) * | 2001-03-01 | 2002-09-04 | Pfizer Products Inc. | Sulfamide derivatives useful as beta3 agonists and pharmaceutical uses thereof |
AR035858A1 (es) | 2001-04-23 | 2004-07-21 | Bayer Corp | Derivados de cromano 2,6-sustituidos,composiciones farmaceuticas,uso de dichos derivados para la manufactura de medicamentos utiles como agonistas adrenorreceptores beta-3 |
US6780859B2 (en) | 2001-09-14 | 2004-08-24 | Bayer Pharmaceuticals Corporation | Benzofuran and dihydrobenzofuran derivatives useful as beta-3 adrenoreceptor agonists |
WO2003072547A1 (en) * | 2002-02-27 | 2003-09-04 | Pfizer Products Inc. | PROCESSES AND INTERMEDIATES USEFUL IN PREPARING β3-ADRENERGIC RECEPTOR AGONISTS |
AU2003209527A1 (en) * | 2002-02-27 | 2003-09-09 | Pfizer Products Inc. | Crystal forms of (r)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol |
US6864268B2 (en) | 2002-02-27 | 2005-03-08 | Pfizer Inc. | β3 adrenergic receptor agonists |
DOP2003000587A (es) * | 2002-02-27 | 2003-08-30 | Pfizer Prod Inc | AGONISTAS DEL RECEPTOR ß3-ADRENERGICO |
WO2003072571A1 (en) * | 2002-02-27 | 2003-09-04 | Pfizer Products Inc. | Salt of a pyridyl ethanolamine derivative and its use as a beta-3-adrenergic receptor agonist |
PL373429A1 (en) * | 2002-07-17 | 2005-08-22 | Lek Pharmaceuticals D.D. | Novel derivatives of pyridylethanol (phenylethyl) amines as inhibitors of cholesterol biosynthesis, processes for their preparation, and pharmaceutical compositions containing them |
GB0220730D0 (en) * | 2002-09-06 | 2002-10-16 | Glaxo Group Ltd | Medicinal compounds |
JP4896518B2 (ja) * | 2002-12-13 | 2012-03-14 | ワイエム・バイオサイエンシズ・オーストラリア・ピーティーワイ・リミテッド | ニコチンアミド系キナーゼ阻害薬 |
BRPI0407386A (pt) * | 2003-02-14 | 2006-02-07 | Kissei Pharmaceutical | Derivados de álcool de amino, composições farmacêuticas contendo os mesmos e uso destes |
CN100418944C (zh) * | 2003-02-14 | 2008-09-17 | 橘生药品工业株式会社 | 氨基醇衍生物、含有所述氨基醇衍生物的药物组合物及其应用 |
EP1679304A4 (en) * | 2003-10-24 | 2006-11-15 | Kissei Pharmaceutical | AMINO ALCOHOL DERIVATIVE, MEDICAL COMPOSITION CONTAINING THEREOF AND ITS USE |
CN100582088C (zh) * | 2003-12-23 | 2010-01-20 | 安斯泰来制药有限公司 | 氨基醇衍生物 |
US7915309B2 (en) * | 2007-06-20 | 2011-03-29 | Protia, Llc | Deuterium-enriched oseltamivir |
US8778998B2 (en) | 2009-04-10 | 2014-07-15 | Auspex Pharmaceuticals, Inc. | Biphenyl-3-carboxylic acid modulators of beta-3-adrenoreceptor |
US9522129B2 (en) | 2010-08-03 | 2016-12-20 | Velicept Therapeutics, Inc. | Pharmaceutical Combination |
KR20130135239A (ko) | 2010-08-03 | 2013-12-10 | 앨씨알엑스, 인크. | 과민성 방광 치료를 위한 베타-3 아드레날린 수용체 작용제 및 무스카린 수용체 길항제의 약학적 배합제 |
US9907767B2 (en) | 2010-08-03 | 2018-03-06 | Velicept Therapeutics, Inc. | Pharmaceutical compositions and the treatment of overactive bladder |
TW201338772A (zh) | 2012-02-09 | 2013-10-01 | Altherx Inc | 藥學組合物 |
WO2014108449A1 (en) | 2013-01-08 | 2014-07-17 | Atrogi Ab | A screening method, a kit, a method of treatment and a compound for use in a method of treatment |
US9956194B2 (en) | 2014-12-03 | 2018-05-01 | Velicept Therapeutics, Inc. | Compositions and methods of using modified release solabegron for lower urinary tract symptoms |
PT3365321T (pt) * | 2015-10-23 | 2024-01-12 | B3Ar Therapeutics Inc | Zwiterião de solabegron e suas utilizações |
GB201714740D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
GB201714734D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
GB201714745D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
GB201714736D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
GB202205895D0 (en) | 2022-04-22 | 2022-06-08 | Atrogi Ab | New medical uses |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2965655D1 (en) * | 1978-06-28 | 1983-07-21 | Beecham Group Plc | Secondary amines, their preparation, pharmaceutical compositions containing them and their use |
GB8519154D0 (en) * | 1985-07-30 | 1985-09-04 | Ici Plc | Aromatic ethers |
DE3934436A1 (de) | 1989-06-01 | 1991-04-18 | Thomae Gmbh Dr K | 2-hydroxy-n-propylamine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
US5061727A (en) | 1990-05-04 | 1991-10-29 | American Cyanamid Company | Substituted 5-(2-((2-aryl-2-hydroxyethyl)amino)propyl)-1,3-benzodioxoles |
NO179246C (no) * | 1991-11-20 | 1996-09-04 | Sankyo Co | Aromatiske amino-alkoholderivater og mellomprodukter til fremstilling derav |
AU2737295A (en) * | 1994-06-09 | 1996-01-04 | Glaxo Group Limited | Phenethanolamine derivatives and their use as atypical beta-adrenoceptor agonists |
-
1998
- 1998-06-13 GB GBGB9812709.5A patent/GB9812709D0/en not_active Ceased
-
1999
- 1999-06-09 ID IDW20010101A patent/ID27841A/id unknown
- 1999-06-09 IL IL14021999A patent/IL140219A0/xx active IP Right Grant
- 1999-06-09 PL PL344865A patent/PL196943B1/pl unknown
- 1999-06-09 JP JP2000554704A patent/JP3471754B2/ja not_active Expired - Lifetime
- 1999-06-09 CN CNB99809630XA patent/CN1214008C/zh not_active Expired - Lifetime
- 1999-06-09 NZ NZ508805A patent/NZ508805A/en not_active IP Right Cessation
- 1999-06-09 KR KR10-2000-7014098A patent/KR100415877B1/ko not_active IP Right Cessation
- 1999-06-09 SK SK1908-2000A patent/SK286256B6/sk not_active IP Right Cessation
- 1999-06-09 EA EA200001172A patent/EA003641B1/ru not_active IP Right Cessation
- 1999-06-09 US US09/719,595 patent/US6251925B1/en not_active Expired - Lifetime
- 1999-06-09 DE DE69926752T patent/DE69926752T2/de not_active Expired - Lifetime
- 1999-06-09 CA CA002334713A patent/CA2334713C/en not_active Expired - Lifetime
- 1999-06-09 TR TR2001/00299T patent/TR200100299T2/xx unknown
- 1999-06-09 DK DK99927923T patent/DK1087943T3/da active
- 1999-06-09 AP APAP/P/2001/002028A patent/AP1687A/en active
- 1999-06-09 AT AT99927923T patent/ATE302189T1/de active
- 1999-06-09 CZ CZ20004648A patent/CZ299172B6/cs not_active IP Right Cessation
- 1999-06-09 BR BRPI9911182-9A patent/BR9911182B1/pt not_active IP Right Cessation
- 1999-06-09 CO CO99036228A patent/CO5060482A1/es unknown
- 1999-06-09 WO PCT/EP1999/003958 patent/WO1999065877A1/en active IP Right Grant
- 1999-06-09 AU AU45103/99A patent/AU753004B2/en not_active Expired
- 1999-06-09 EP EP99927923A patent/EP1087943B1/en not_active Expired - Lifetime
- 1999-06-09 RS YUP-792/00A patent/RS49921B/sr unknown
- 1999-06-09 AR ARP990102733A patent/AR029301A1/es active IP Right Grant
- 1999-06-09 SI SI9930827T patent/SI1087943T1/sl unknown
- 1999-06-09 HU HU0102668A patent/HUP0102668A3/hu unknown
- 1999-06-09 EE EEP200000744A patent/EE04435B1/xx not_active IP Right Cessation
- 1999-06-09 ES ES99927923T patent/ES2245107T3/es not_active Expired - Lifetime
- 1999-06-10 PE PE1999000517A patent/PE20000726A1/es not_active Application Discontinuation
- 1999-06-10 MY MYPI99002368A patent/MY119542A/en unknown
- 1999-06-10 EG EG70199A patent/EG23856A/xx active
- 1999-06-16 TW TW088110054A patent/TWI244471B/zh not_active IP Right Cessation
-
2000
- 2000-12-08 IS IS5760A patent/IS2277B/is unknown
- 2000-12-11 IL IL140219A patent/IL140219A/en not_active IP Right Cessation
- 2000-12-12 ZA ZA200007417A patent/ZA200007417B/en unknown
- 2000-12-12 NO NO20006319A patent/NO318782B1/no not_active IP Right Cessation
- 2000-12-13 HR HR20000854A patent/HRP20000854B1/xx not_active IP Right Cessation
-
2001
- 2001-07-11 HK HK01104848A patent/HK1034253A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100415877B1 (ko) | 치료용 비아릴 유도체 | |
NL1028947C2 (nl) | Gesubstitueerde methylaryl- of heteroarylamideverbindingen. | |
CA2758894C (en) | Novel thyroid hormone .beta. receptor agonist | |
KR880002001B1 (ko) | 1,3-디옥산-5-일 알케논산의 제조방법 | |
TWI466877B (zh) | 雙環式化合物及其醫藥用途 | |
US10676438B2 (en) | KCNQ2-5 channel activator | |
EA018225B1 (ru) | Соединения оксадиазоантрацена для лечения диабета | |
WO2013104257A1 (zh) | 多环类衍生物、其制备方法及其在医药上的应用 | |
WO2014187343A1 (zh) | 苯并呋喃衍生物、其制备方法及其在医药上的应用 | |
KR20140048239A (ko) | 아미노 프로판디올 유도체, 제조방법 및 약제학적 조성물 및 사용 | |
KR100192622B1 (ko) | 페네타놀아민 화합물 | |
JP2011515406A (ja) | 治療用の置換シクロペンタン類 | |
KR19990076688A (ko) | 생물학적으로 활성인 벤조티아졸론 에탄아민 | |
CN104844533B (zh) | 含五元芳杂环的氨基丙二醇类化合物、其制备方法及其医药用途 | |
KR102640385B1 (ko) | 고혈압 및/또는 폐 섬유증 치료용 조성물 | |
NZ736165A (en) | Compositions for the treatment of kidney and/or liver disease | |
WO2001083453A1 (fr) | Nouveaux composes tricycliques substitues | |
MXPA00012389A (en) | Therapeutic biaryl derivatives | |
CZ20032085A3 (cs) | Fenethanolaminové deriváty | |
WO2001042217A1 (en) | Beta-3 adrenoceptor agonists | |
WO2012163264A1 (zh) | 三白脂素结构简化物,其制法和其药物组合物与用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20121226 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20140219 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20150102 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20151224 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20161229 Year of fee payment: 14 |
|
FPAY | Annual fee payment |
Payment date: 20171227 Year of fee payment: 15 |
|
FPAY | Annual fee payment |
Payment date: 20190103 Year of fee payment: 16 |
|
EXPY | Expiration of term |